Guangzhou Baiyunshan Hanfang Launches HighPurity MCT API for Global Markets

Domestic Tech Breakthrough Ends Foreign Monopoly; EU CEP, FDA-Compliant Product Serves Global Pharma

GUANGZHOU, CHINA – 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading Chinese supplier of high-end pharmaceutical lipid excipients, today announces the global launch of its domestically developed high-purity medium chain triglyceride (MCT) active pharmaceutical ingredient (API). This breakthrough product addresses the long-standing reliance on imported MCT APIs in the global pharma and nutraceutical industries, featuring 99%+ purity, green manufacturing processes, and full compliance with international regulatory standards. The API is now available for global orders, with mass production and worldwide shipping starting immediately.

Core Technical Breakthroughs & Product Highlights

1. 99%+ Purity & Consistent Quality: The high-purity MCT API achieves over 99% purity through the company’s proprietary integrated green technology, combining supercritical CO₂ extraction, membrane separation, and chromatographic separation. This advanced process replaces traditional polluting methods, ensuring stable product quality that meets the strict requirements of high-end injectable formulations and special medical foods.
2. Green Manufacturing Compliance: The production process adheres to environmental protection standards, earning the company the national "Green Factory" certification. It reduces waste emissions by 30% compared to traditional manufacturing, aligning with global sustainability trends.
3. Ending Foreign Monopoly: Prior to this launch, global high-purity MCT APIs were dominated by foreign suppliers, with domestic localization rate at only 10%. Guangzhou Baiyunshan Hanfang’s product raises this rate to 90%, breaking long-term foreign market control and ensuring stable supply for global clients.

Global Compliance & Certifications

The high-purity MCT API has obtained EU CEP certification and completed US FDA US-DMF registration, meeting the regulatory requirements of the EU, North America, Asia-Pacific, and other major global markets. It is also compliant with Mexico Cofepris and India DCGI standards, enabling seamless access to diverse international markets.

Supply & Customization Services

The high-purity MCT API is now available for global orders through the official website (http://byshanhanfang.com/) and authorized global distributors. Mass production and worldwide shipping have commenced immediately. In addition to standard products, the company offers customized services including tailored purity specifications and specialized packaging to meet the unique needs of pharmaceutical, nutraceutical, and research institutions.

Executive Quote

"The launch of our high-purity MCT API marks a significant milestone in China’s pharmaceutical excipient industry, realizing domestic substitution for a critical high-end product," said Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center at Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. "We will continue to leverage our technological advantages to provide reliable, cost-effective solutions for global clients, contributing to the stability of the global pharmaceutical supply chain.

Industry Context & Corporate Strategy

Global demand for high-purity pharmaceutical lipid excipients is growing rapidly, driven by the expansion of injectable drug markets and the rising demand for special medical foods. Guangzhou Baiyunshan Hanfang’s high-purity MCT API addresses this demand by offering a domestically produced alternative that meets international quality standards, strengthening its position as a trusted global supplier.

Future Plans

Looking ahead, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. will continue to invest in R&D of high-end pharmaceutical lipid excipients and APIs, expanding its product portfolio to cover more critical "bottleneck" products. The company will also enhance its global sales and service network, providing localized support for clients in more countries and regions.

About Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.

Founded in 1998, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. is a state-owned enterprise under Guangzhou Pharmaceutical Holdings (GPH). It is a national specialized, sophisticated, unique, and new "Little Giant" enterprise, operating the only national engineering research center for traditional Chinese medicine process technology and new drug development. The company specializes in high-end pharmaceutical lipid excipients, APIs, health products, and technical services, serving over 1,000 clients in more than 20 countries and regions. With over 240 patents and multiple international certifications, the company is committed to technological innovation and safeguarding global pharmaceutical supply chain security. For more information, visit http://byshanhanfang.com/.